Seal Rock Therapeutics, Inc.
Seattle, WA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 600 Stewart St Ste 400, Seattle, WA 98101, USA
- Website
- sealrocktx.com
- Founded
- 2016
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Seal Rock Therapeutics, Inc. is a for-profit corporate entity based in Seattle, Washington, specializing in developing innovative pharmaceutical therapies targeting complex liver and neurological diseases. Registered in SAM.gov since November 2020, the company focuses on developing novel kinase inhibitors, particularly ASK1 (Apoptosis Signal-regulating Kinase 1) inhibitors, to address unmet medical needs in various disease areas. Their research and development efforts are primarily centered on creating therapeutic interventions for challenging medical conditions with limited existing treatment options.
The company has secured multiple federal grant awards from prestigious agencies, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Defense Health Agency, and National Institute on Alcohol Abuse and Alcoholism. These grants support preclinical research on their lead compound SRT-015, targeting conditions such as neonatal biliary atresia, acute alcoholic hepatitis, and potentially neurological disorders like ALS. The grants, ranging from approximately $346,910 to support specific research projects, have enabled Seal Rock Therapeutics to conduct extensive studies exploring the therapeutic potential of ASK1 inhibition. Their research involves developing and testing SRT-015 in various animal models, with objectives including establishing optimal dosing, evaluating efficacy in treating inflammatory and fibrotic liver conditions, and investigating potential applications in neurological disease management. The company's grant-funded work demonstrates a comprehensive approach to developing innovative pharmaceutical interventions through rigorous scientific research and preclinical testing.
Quick answers
Is Seal Rock Therapeutics, Inc. registered in SAM.gov?
Yes. Seal Rock Therapeutics, Inc.'s SAM.gov registration is active through July 1, 2027.
What is Seal Rock Therapeutics, Inc.'s CAGE code?
Seal Rock Therapeutics, Inc.'s CAGE code is 8SVE5, and its Unique Entity ID (UEI) is P23WBJRKFLA1.
What is Seal Rock Therapeutics, Inc.'s most recent federal award?
Seal Rock Therapeutics, Inc.'s most recent federal grant award is Targeting ASK1 as a novel therapy to treat biliary atresia (R41DK143902), from National Institute of Diabetes and Digestive and Kidney Diseases (NIH), on September 15, 2025.
On GovTribe
See Seal Rock Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors